GO:0002820 negative regulation of adaptive immune response: Immune Checkpoint Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002820 (negative regulation of adaptive immune response) describes any process that stops, prevents, or reduces the frequency, rate, or extent of an adaptive immune response.
• Adaptive immune responses are initiated when pattern-recognition receptors on innate cells detect pathogens and prime T and B lymphocytes.
• Negative regulation is essential for self-tolerance and for preventing immunopathology after infection resolves.
• Tumors exploit this process through adaptive immune resistance, including PD-1/PD-L1 signaling, which can be reversed by checkpoint blockade.
• The tumor microenvironment contains fibroblast and macrophage populations that suppress adaptive immunity via cytokines such as IL-1 family members [4,5,8].
• Glyco-immune barriers such as sialylated CD43 can restrain antileukemic immunity, illustrating diverse molecular modes of negative regulation.
Description
GO:0002820, negative regulation of adaptive immune response, is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of an adaptive immune response. Adaptive immunity depends on the activation, clonal expansion, and effector function of T and B lymphocytes, which are triggered after innate pattern-recognition receptors sense microbial products and present antigen. Because unrestrained adaptive immunity can damage host tissues, multiple layers of negative regulation exist to contract responses after pathogen clearance and to maintain tolerance to self. Understanding this term is therefore central to immunology, autoimmunity, transplantation, and cancer immunotherapy research. In cancer, tumors co-opt negative regulatory circuits to evade T cell attack, a phenomenon termed adaptive immune resistance. Single-cell studies of pancreatic and hepatic tumors have revealed that specific stromal and myeloid populations shape the immunosuppressive landscape and limit adaptive immunity [4,6]. Interleukin-1 family cytokines and their receptors provide one well-characterized axis through which innate signals modulate the strength and duration of adaptive responses. More recently, glyco-immune barriers formed by sialylated CD43 were shown to restrain antileukemic immunity, highlighting that negative regulation can also be mediated by glycan-based checkpoints. Targeting negative regulatory nodes such as USP7 in tumor-associated macrophages can reprogram the microenvironment and enhance anti-tumor immunity. For researchers, GO:0002820 provides a conceptual framework to annotate genes and pathways that dampen lymphocyte activation, and to design CRISPR screens that identify new checkpoints [3,8].
negative regulation of adaptive immune response At A Glance
| GO ID | GO:0002820 |
|---|---|
| GO term | negative regulation of adaptive immune response |
| Ontology | biological_process |
| Synonym | down regulation of adaptive immune response; down-regulation of adaptive immune response; downregulation of adaptive immune response; inhibition of adaptive immune response |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of an adaptive immune response |
| Biological context | Maintains self-tolerance and limits immunopathology after infection |
| Disease relevance | Exploited by tumors to evade T cell attack (adaptive immune resistance) |
| Key cell types | T cells, B cells, regulatory T cells, tumor-associated macrophages, fibroblasts [3,4,8] |
| Example mediators | PD-1/PD-L1, IL-1 family cytokines, sialylated CD43, USP7 [3,5,7,8] |
What Is GO:0002820?
In plain terms, GO:0002820 describes the biological brakes that slow down or shut off the adaptive immune system. Formally, it is any process that stops, prevents, or reduces the frequency, rate, or extent of an adaptive immune response. This includes cell-intrinsic inhibitory receptors on lymphocytes, suppressive cytokines, regulatory cell populations, and metabolic or glycan barriers that limit T and B cell function [3,5,7].
Why Is negative regulation of adaptive immune response Important in Cell Biology?
Negative regulation of adaptive immunity is essential for preventing autoimmunity and for resolving inflammation, but it is also a major barrier to effective cancer immunotherapy [1,3]. Understanding the molecules and cell populations that enforce this brake allows researchers to design targeted interventions, such as checkpoint blockade, that selectively release adaptive immunity against tumors while preserving tolerance [3,8].
• Prevents autoimmunity by restraining self-reactive T and B lymphocytes.
• Limits tissue damage and immunopathology after pathogen clearance.
• Is hijacked by tumors to establish adaptive immune resistance.
• PD-1 blockade can reverse negative regulation and induce tumor responses.
• Tumor-associated macrophages can suppress adaptive immunity via USP7-dependent programs.
• IL-1 family cytokines modulate the magnitude and duration of adaptive responses.
• Glyco-immune barriers such as sialylated CD43 restrain antileukemic immunity.
• Fibroblast lineages in pancreatic tumors can support or suppress anti-tumor immunity.
• Immune-specific hepatocellular carcinoma classes show distinct negative regulatory landscapes.
• Neutrophils can influence the transition from innate to adaptive immunity.
What Happens During negative regulation of adaptive immune response?
Initiation and antigen presentation
In simple terms: First, innate sensors detect danger and help activate lymphocytes.
Adaptive immune responses begin when pattern-recognition receptors such as Toll-like receptors on innate cells detect microbial products and promote antigen presentation to T and B lymphocytes. This priming step is required for lymphocyte activation, but it also sets the stage for subsequent negative feedback that prevents excessive responses [1,2].
Checkpoint receptor engagement
In simple terms: Inhibitory receptors on T cells act like brakes once they engage their ligands.
Negative regulation often occurs through inhibitory receptors such as PD-1 on T cells. In tumors, PD-1 engagement by PD-L1 suppresses T cell effector function, and blockade of this interaction restores anti-tumor responses. This checkpoint axis is a canonical example of GO:0002820 activity in cancer.
Suppressive cytokine networks
In simple terms: Signaling molecules can tell immune cells to calm down.
Cytokines including interleukin-1 family members shape the intensity and duration of adaptive immunity. Tumor-associated macrophages can be reprogrammed by targeting USP7, which modulates anti-tumor immune responses and alters the suppressive microenvironment. These cytokine and signaling networks enforce negative regulation on lymphocytes [5,8].
Stromal and glycan barriers
In simple terms: Physical and glycan-based barriers can block immune cells from doing their job.
Specific fibroblast lineages in pancreatic tumors can support or restrain anti-tumor immunity, indicating that stromal cells contribute to negative regulation. Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity, demonstrating that glycans can directly inhibit adaptive effector function. These barriers represent non-cytokine modes of GO:0002820 [4,7].
Resolution and tolerance
In simple terms: After the threat is gone, the system turns itself off to avoid friendly fire.
Once pathogens are cleared, negative regulatory processes contract the adaptive response and maintain tolerance to self. Neutrophils and other innate cells participate in the transition from active immunity to resolution. Failure of this resolution step can contribute to autoimmunity or chronic inflammation.
Key Genes Involved in GO:0002820 negative regulation of adaptive immune response
The following genes and proteins are experimentally linked to negative regulation of adaptive immune responses in cancer, infection, and immune homeostasis.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDCD1 (PD-1) | Inhibitory receptor on T cells | Target of checkpoint blockade in cancer |
| CD274 (PD-L1) | Ligand for PD-1 | Mediates adaptive immune resistance in tumors |
| IL1B | Interleukin-1 family cytokine | Modulates innate-to-adaptive immune signaling |
| IL1RN | Interleukin-1 receptor antagonist | Regulates IL-1 family activity |
| USP7 | Deubiquitinase in macrophages | Reprograms tumor-associated macrophages and anti-tumor immunity |
| CD43 | Sialylated surface glycoprotein | Forms glyco-immune barrier restraining antileukemic immunity |
| TLR4 | Pattern-recognition receptor | Initiates innate signals that shape adaptive responses |
| MYD88 | TLR adaptor protein | Transduces innate signals upstream of adaptive immunity |
| FOXP3 | Regulatory T cell transcription factor | Supports suppressive lymphocyte populations |
| IL10 | Anti-inflammatory cytokine | Dampens adaptive effector responses |
| TGFB1 | Immunosuppressive cytokine | Limits T cell activation in tumors |
| CSF1R | Macrophage growth factor receptor | Controls tumor-associated macrophage populations |
| CXCL12 | Stromal chemokine | Shapes immune exclusion in tumors |
| FAP | Fibroblast activation protein | Marks immunosuppressive fibroblast lineages |
| ARG1 | Arginase-1 in myeloid cells | Depletes arginine and suppresses T cells |
| IDO1 | Tryptophan-catabolizing enzyme | Suppresses adaptive immunity in tumors |
| LGALS9 | Galectin-9 | Engages inhibitory receptors on T cells |
How Is negative regulation of adaptive immune response Regulated?
Negative regulation of adaptive immunity is itself tightly controlled. Pattern-recognition receptor signaling through TLRs and MYD88 provides initial activation cues that are later counterbalanced by inhibitory pathways. Interleukin-1 family cytokines and their receptors fine-tune the strength of adaptive responses. In tumors, USP7 activity in macrophages modulates the suppressive microenvironment and can be targeted to enhance anti-tumor immunity. Glycan-modifying enzymes that generate sialylated CD43 establish a barrier that restrains lymphocyte function. These layers ensure that adaptive immunity is potent but self-limiting.
negative regulation of adaptive immune response and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDCD1 | Cancer adaptive immune resistance | PD-1 knockout T cells in co-culture assays |
| CD274 | Tumor immune evasion | PD-L1 overexpression in tumor lines |
| USP7 | Lung cancer immunosuppression | USP7 knockout macrophages in tumor models |
| CD43 | Leukemia glyco-immune barrier | Sialylation-deficient leukemia cells |
| IL1B | Inflammatory and autoimmune conditions | IL-1 family cytokine knockout mice |
Cancer and adaptive immune resistance
Tumors frequently exploit negative regulation of adaptive immunity to evade T cell attack, a process called adaptive immune resistance. PD-1 blockade can reverse this resistance and induce responses in some patients. Tumor-associated macrophages and fibroblast lineages further suppress immunity through USP7-dependent and stromal programs [4,8]. Immune-specific hepatocellular carcinoma classes display distinct molecular features that shape the negative regulatory landscape.
Leukemia and glyco-immune barriers
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity, providing a non-checkpoint mechanism of negative regulation. This highlights glycan-directed strategies as potential therapeutic avenues.
Autoimmunity and tolerance
When negative regulation fails, self-reactive lymphocytes can escape control and drive autoimmunity. Conversely, excessive negative regulation can permit chronic infection or tumor progression [1,3]. Understanding the balance is critical for designing immunotherapies that are effective without causing autoimmunity [1,3].
From negative regulation of adaptive immune response-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PD-1 loss enhance T cell killing? | PDCD1 knockout T cells |
| Does PD-L1 overexpression suppress immunity? | CD274 knock-in tumor cells |
| Does USP7 inhibition reprogram macrophages? | USP7 knockout or point-mutation macrophages |
| Does CD43 sialylation restrain leukemia immunity? | CD43 knock-in with sialylation mutations |
| How do IL-1 family cytokines tune adaptive responses? | IL1B or IL1RN knockout mice |
| Which fibroblast lineages suppress anti-tumor immunity? | FAP-tagged knock-in reporter models |
How to Study the negative regulation of adaptive immune response Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Single-cell RNA-seq | Cell-type-specific gene expression | Tumor microenvironment profiling |
| CRISPR knockout screens | Gene loss effects on immune response | Discovery of negative regulators [3,8] |
| Co-culture cytotoxicity assays | T cell killing of target cells | Checkpoint blockade studies |
| Glycan profiling | Sialylation and glycan structures | Glyco-immune barrier analysis |
| Cytokine ELISA | IL-1 family and other cytokine levels | Inflammation and tolerance studies |
| Macrophage reprogramming assays | USP7-dependent macrophage phenotypes | Lung cancer immunology |
| Flow cytometry | Immune cell populations and activation markers | Immunophenotyping |
Single-cell transcriptomics
Single-cell RNA sequencing can define suppressive cell populations such as fibroblast lineages and macrophage subsets in tumors. This method reveals heterogeneity in negative regulatory programs across patients [4,6].
Functional immune assays
Co-culture assays with T cells and target cells measure the impact of checkpoint molecules such as PD-1/PD-L1 on adaptive immunity. Cytokine release and cytotoxicity readouts quantify negative regulation.
CRISPR screens
Genome-wide CRISPR screens can identify genes whose loss enhances or suppresses adaptive immune responses [3,8]. These screens are powerful for discovering new negative regulators [3,8].
Glycan and biochemical profiling
Glycan profiling and lectin-based assays detect sialylated structures such as CD43 that form immune barriers. Biochemical assays can measure USP7 activity and IL-1 family signaling [5,8].
How CRISPR Can Be Used to Study GO:0002820 negative regulation of adaptive immune response
Knockout
CRISPR knockout of negative regulators such as PDCD1 or USP7 can release adaptive immunity and enhance anti-tumor responses [3,8]. Knockout models are essential to test causality of candidate genes in GO:0002820 [3,8].
Point Mutation
Point mutations can dissect specific domains of inhibitory receptors or signaling molecules, such as PD-1 tyrosine motifs or USP7 catalytic residues [3,8]. These models reveal which molecular features are required for negative regulation [3,8].
Knock-in
Knock-in of reporters or tagged alleles, such as FAP-tagged fibroblasts or CD43 sialylation variants, allows tracking of suppressive populations and glycan barriers [4,7]. Knock-in models help visualize negative regulation in vivo [4,7].
Overexpression
Overexpression of PD-L1 or IL-1 family members can model enhanced negative regulation and immune evasion [3,5]. These models are useful for testing drugs that block suppressive pathways [3,5].
How EDITGENE Supports negative regulation of adaptive immune response Research
Researchers studying negative regulation of adaptive immune response-related genes often need to determine whether a candidate gene is causally involved in dampening lymphocyte activity, and which domains or residues mediate that effect. EDITGENE provides end-to-end CRISPR cell model services to answer these questions with publication-grade rigor.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of adaptive immune response research.
Frequently Asked Questions About negative regulation of adaptive immune response
What is negative regulation of adaptive immune response (GO:0002820)?
It is any process that stops, prevents, or reduces the frequency, rate, or extent of an adaptive immune response.
What genes are involved in negative regulation of adaptive immune response?
Key genes include PDCD1, CD274, USP7, CD43, IL1B, and IL1RN, among others [3,5,7,8].
How does PD-1 contribute to negative regulation of adaptive immunity?
PD-1 engagement by PD-L1 suppresses T cell effector function, and blockade reverses this suppression.
What is adaptive immune resistance in cancer?
It is the process by which tumors exploit negative regulatory pathways to evade T cell attack.
Can CRISPR screens identify new negative regulators of adaptive immunity?
Yes, genome-wide CRISPR screens have been used to discover genes that modulate anti-tumor immunity [3,8].
What role do tumor-associated macrophages play in negative regulation?
They can suppress adaptive immunity, and targeting USP7 in macrophages reprograms them to enhance anti-tumor responses.
How do IL-1 family cytokines affect adaptive immunity?
They modulate the strength and duration of adaptive immune responses.
What is a glyco-immune barrier?
It is a glycan-based structure, such as sialylated CD43, that restrains immune effector function.
Which experimental models are used to study GO:0002820?
Knockout, knock-in, point-mutation, and overexpression models in cell lines and mice are commonly used [3,4,7,8].
Why is negative regulation of adaptive immunity important for immunotherapy?
Understanding it allows researchers to design checkpoint blockade and other strategies that release anti-tumor immunity [3,8].
Conclusion
GO:0002820, negative regulation of adaptive immune response, is a central biological process that balances protective immunity with tolerance and tissue protection. Its dysregulation contributes to cancer immune evasion, autoimmunity, and chronic infection [1,3]. Key molecular players include PD-1/PD-L1, IL-1 family cytokines, USP7, and sialylated CD43, each offering therapeutic opportunities [3,5,7,8]. CRISPR-based models are indispensable for dissecting these pathways and for discovering new checkpoints [3,8]. EDITGENE supports this research with comprehensive gene editing and screening services tailored to GO:0002820.
References
- 1. Liew PX et al.. 2019. The Neutrophil's Role During Health and Disease.. Physiol Rev 99(2):1223-1248 PMID: 30758246
- 2. Kawai T et al.. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.. Nat Immunol 11(5):373-84 PMID: 20404851
- 3. Tumeh PC et al.. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance.. Nature 515(7528):568-71 PMID: 25428505
- 4. Hutton C et al.. 2021. Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity.. Cancer Cell 39(9):1227-1244.e20 PMID: 34297917
- 5. Garlanda C et al.. 2013. The interleukin-1 family: back to the future.. Immunity 39(6):1003-18 PMID: 24332029
- 6. Sia D et al.. 2017. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.. Gastroenterology 153(3):812-826 PMID: 28624577
- 7. Chung J et al.. 2026. Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity.. Science 392(6794):eady5196 PMID: 41955354
- 8. Dai X et al.. 2020. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer.. Theranostics 10(20):9332-9347 PMID: 32802195
